Avyxa Holdings Patent-Cliff Exposure & CMS Drug Spending Portfolio

Avyxa Holdings (US): 11 reconciled FDA prescription therapies, $2.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies11
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$2.4M
California HCAI SB 17 Filings1 WAC filings (max 400.0% 2-yr change)